SCHEMBL420831

SCHEMBL420831

COC(=O)c1cc(Cl)ccc1NC(=O)C=Cc1cccc(-c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.57
MEN1 O00255 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KMT2A Q03164 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
MMP1 P03956 7/20 0.52
MMP2 P08253 7/20 0.52
MMP9 P14780 7/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
KDM4E B2RXH2 2/20 0.52
NPSR1 Q6W5P4 2/20 0.50
TRPA1 O75762 1/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
MAOB P27338 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420830 1.00 EGFR (0.57) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL418157 0.91 ALDH1A1 (0.59) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL418156 0.91 ALDH1A1 (0.59) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL417073 0.89 EGFR (0.62) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL417074 0.89 EGFR (0.62) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL417436 0.88 ALDH1A1 (0.47) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL417435 0.88 ALDH1A1 (0.47) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL418392 0.86 MAOB (0.53) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL418393 0.86 MAOB (0.53) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL419085 0.83 SERPINE1 (0.55) EGFRMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 EGFR 4283/4885MEN1 844/4885NPC1 893/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 EGFR 4283/4885MEN1 844/4885NPC1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.